down arrow

Meghmani Fineche

  • Market Cap: Mid Cap
  • Industry: Chemicals
  • ISIN: INE071N01016
  • NSEID: MFL
  • BSEID: 543332
INR
1,706.10
26.1 (1.55%)
BSENSE

Apr 11

BSE+NSE Vol: 28.72 k

Click here to access the older version
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1,706.101,755.80

52 Week

1,107.452,408.35
Valuation
Technical
Day's Volume

CASH

28.72 k (-16.26%) Volume

Shareholding (Dec 2024)

FII

3.01%

Held by 77 FIIs

DII

4.33%

Held by 4 DIIs

Promoter

68.94%

Is Epigral technically bullish or bearish?

28-Apr-2025

Epigral is currently exhibiting a mildly bullish trend, with recent stock price increases and strong weekly performance, despite some mixed signals from daily moving averages and monthly MACD indicators. Overall, the short-term outlook leans towards bullish.

Epigral is currently exhibiting a mildly bullish technical trend. The stock price has recently increased, and the company has shown a strong performance over the past week, outperforming the Sensex. Key technical indicators support this bullish outlook on a weekly basis, particularly the MACD and Bollinger Bands. However, it's worth noting that there are some mixed signals, as the moving averages indicate a mildly bearish trend on a daily basis and the MACD remains mildly bearish on a monthly scale. Overall, while there are some conflicting signals, the prevailing trend leans towards bullish in the short term.

Read More

Is Epigral overvalued or undervalued?

28-Apr-2025

Epigral is currently considered overvalued, with a price of 1,779.85 significantly higher than its previous close of 1,680.00, and a valuation grade shifting from fair to expensive. Despite strong financial metrics, its high price-to-earnings and EV to EBITDA ratios indicate it is trading at a premium compared to industry peers.

Based on the latest information, Epigral appears to be overvalued. The company's valuation grade has shifted from fair to expensive, and its current price of 1,779.85 is significantly higher than its previous close of 1,680.00. While Epigral has delivered impressive stock returns of 31.19% over the past year and 75.81% over three years, its price-to-earnings (PE) ratio of 22.06 and EV to EBITDA ratio of 12.37 suggest that it is trading at a premium compared to its peers in the chemicals industry.<BR><BR>Additionally, while the company has strong financial metrics, such as a return on capital employed (ROCE) of 22.09% and a return on equity (ROE) of 20.96%, the overall valuation relative to its competitors indicates that it may be priced higher than its intrinsic value. Therefore, considering these factors, it would be reasonable to conclude that Epigral is currently overvalued.

Read More

Are Epigral latest results good or bad?

28-Apr-2025

Epigral's latest results are positive, with record operating profit and a significant increase in profit after tax, but the company faces challenges with liquidity and slower receivables collection. Overall, while growth is strong, addressing these issues is crucial for sustained performance.

Epigral's latest results are generally positive, indicating good performance in the third quarter of FY24-25. The company reported a record high operating profit (PBDIT) of Rs 182.51 crore, showing consistent growth over the past five quarters. Profit After Tax (PAT) also improved significantly, reaching Rs 103.63 crore, which is a 41.2% increase compared to the average PAT of the previous four quarters. Additionally, net sales for the half-year period increased by 33.87%, totaling Rs 1,271.30 crore.<BR><BR>However, there are some challenges that the company is facing. The operating profit to interest ratio has deteriorated to -2,607.29 times, and there has been a decline in cash and cash equivalents, which fell to Rs 6.08 crore. Furthermore, the debtors turnover ratio decreased to 9.04 times, suggesting that the company is taking longer to recover payments from its customers.<BR><BR>In summary, while Epigral's financial results show strong growth and profitability, the company must address its liquidity issues and the slower collection of receivables to maintain its positive trajectory.

Read More

Should I buy, sell or hold Epigral?

28-Apr-2025

It is advisable to hold your position in Epigral due to its strong management efficiency, recent positive performance, and favorable debt levels, despite a sideways technical trend and limited long-term growth potential.

Based on the current analysis of Epigral, it is advisable to hold your position in the stock. The company demonstrates high management efficiency with a return on capital employed (ROCE) of 24.51%, indicating effective use of capital. Additionally, it has reported positive results for the last four consecutive quarters, with net sales growing significantly by 33.87% and achieving a record PBDIT of Rs 182.51 crore.<BR><BR>The debt-equity ratio is also favorable at 0.64 times, suggesting a manageable level of debt. Furthermore, the stock has outperformed the market over the past year, generating a return of 37.34%, which is substantially higher than the BSE 500's return of 4.34%.<BR><BR>However, it's important to note that the technical trend is currently sideways, indicating a lack of clear price momentum. While the company has shown strong short-term performance, its long-term growth appears limited, with an annual operating profit growth rate of 19.71% over the last five years. The valuation metrics suggest that the stock is relatively expensive, with a PEG ratio of 0.3, although it is trading at a discount compared to its peers.<BR><BR>In summary, holding your investment in Epigral seems prudent given its strong recent performance and management efficiency, while being mindful of the potential limitations in long-term growth.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Dashboard
1

Poor long term growth as Operating profit has grown by an annual rate 19.71% of over the last 5 years

 
2

Stock is technically in a Mildly Bearish range

stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Chemicals

stock-summary
Market cap

INR 7,360 Cr (Mid Cap)

stock-summary
P/E

21.00

stock-summary
Industry P/E

41

stock-summary
Dividend Yield

0.44%

stock-summary
Debt Equity

0.64

stock-summary
Return on Equity

20.96%

stock-summary
Price to Book

5.18

Revenue and Profits (1 Year):
Net Sales:
645 Cr
(Quarterly Results - Dec 2024)
Net Profit:
104 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0.44%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.53%
0.14%
-2.39%
6 Months
-23.77%
0.12%
-23.65%
1 Year
25.76%
0.58%
26.34%
2 Years
77.57%
1.05%
78.62%
3 Years
68.53%
1.03%
69.56%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Latest dividend: 2.5 per share ex-dividend date: Feb-07-2025

Risk Adjusted Returns v/s Sensex stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
23.14%
EBIT Growth (5y)
19.71%
EBIT to Interest (avg)
8.54
Debt to EBITDA (avg)
2.46
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.85
Tax Ratio
33.47%
Dividend Payout Ratio
10.61%
Pledged Shares
0
Institutional Holding
7.34%
ROCE (avg)
20.55%
ROE (avg)
26.85%
Valuation key factors
Factor
Value
P/E Ratio
21
Industry P/E
41
Price to Book Value
5.18
EV to EBIT
14.44
EV to EBITDA
11.75
EV to Capital Employed
3.55
EV to Sales
3.33
PEG Ratio
0.29
Dividend Yield
0.44%
ROCE (Latest)
22.09%
ROE (Latest)
20.96%
Tecnicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 8 Schemes (4.15%)

FIIs

Held by 77 FIIs (3.01%)

Promoter with highest holding

Ashishbhai Natawarlal Soparkar (14.65%)

Highest Public shareholder

Hsbc Focused Fund (2.63%)

Individual Investors Holdings

17.37%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is 3.06% vs -3.86% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is 27.47% vs -5.32% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "645.24",
          "val2": "626.06",
          "chgp": "3.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "182.51",
          "val2": "178.43",
          "chgp": "2.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "-0.07",
          "val2": "27.32",
          "chgp": "-100.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "103.63",
          "val2": "81.30",
          "chgp": "27.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "28.29%",
          "val2": "28.50%",
          "chgp": "-0.21%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2024 is 36.89% vs -14.27% in Sep 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2024 is 140.53% vs -65.14% in Sep 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,277.26",
          "val2": "933.04",
          "chgp": "36.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "354.83",
          "val2": "203.10",
          "chgp": "74.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "41.57",
          "val2": "39.61",
          "chgp": "4.95%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "167.17",
          "val2": "69.50",
          "chgp": "140.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "27.78%",
          "val2": "21.77%",
          "chgp": "6.01%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is 36.88% vs -13.63% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is 128.37% vs -57.12% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,922.50",
          "val2": "1,404.56",
          "chgp": "36.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "537.34",
          "val2": "325.87",
          "chgp": "64.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "41.50",
          "val2": "59.80",
          "chgp": "-30.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "270.80",
          "val2": "118.58",
          "chgp": "128.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "27.95%",
          "val2": "23.20%",
          "chgp": "4.75%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2024 is -11.84% vs 41.10% in Mar 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2024 is -44.56% vs 39.76% in Mar 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'24",
        "Mar'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,929.19",
          "val2": "2,188.40",
          "chgp": "-11.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "481.20",
          "val2": "688.94",
          "chgp": "-30.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "73.49",
          "val2": "65.50",
          "chgp": "12.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "195.87",
          "val2": "353.29",
          "chgp": "-44.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "24.94%",
          "val2": "31.48%",
          "chgp": "-6.54%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQstock-summary
Dec'24
Sep'24
Change(%)
Net Sales
645.24
626.06
3.06%
Operating Profit (PBDIT) excl Other Income
182.51
178.43
2.29%
Interest
-0.07
27.32
-100.26%
Exceptional Items
0.00
0.00
Consolidate Net Profit
103.63
81.30
27.47%
Operating Profit Margin (Excl OI)
28.29%
28.50%
-0.21%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2024 is 3.06% vs -3.86% in Sep 2024

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2024 is 27.47% vs -5.32% in Sep 2024

All Quarterly Resultsstock-summary
Half Yearly Results Snapshot (Consolidated) - Sep'24stock-summary
Sep'24
Sep'23
Change(%)
Net Sales
1,277.26
933.04
36.89%
Operating Profit (PBDIT) excl Other Income
354.83
203.10
74.71%
Interest
41.57
39.61
4.95%
Exceptional Items
0.00
0.00
Consolidate Net Profit
167.17
69.50
140.53%
Operating Profit Margin (Excl OI)
27.78%
21.77%
6.01%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

Growth in half year ended Sep 2024 is 36.89% vs -14.27% in Sep 2023

Direction Arrows
Consolidated Net Profit

Growth in half year ended Sep 2024 is 140.53% vs -65.14% in Sep 2023

All Half Yearly Resultsstock-summary
Nine Monthly Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
1,922.50
1,404.56
36.88%
Operating Profit (PBDIT) excl Other Income
537.34
325.87
64.89%
Interest
41.50
59.80
-30.60%
Exceptional Items
0.00
0.00
Consolidate Net Profit
270.80
118.58
128.37%
Operating Profit Margin (Excl OI)
27.95%
23.20%
4.75%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2024 is 36.88% vs -13.63% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in nine months ended Dec 2024 is 128.37% vs -57.12% in Dec 2023

All Nine Monthly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Mar'24stock-summary
Mar'24
Mar'23
Change(%)
Net Sales
1,929.19
2,188.40
-11.84%
Operating Profit (PBDIT) excl Other Income
481.20
688.94
-30.15%
Interest
73.49
65.50
12.20%
Exceptional Items
0.00
0.00
Consolidate Net Profit
195.87
353.29
-44.56%
Operating Profit Margin (Excl OI)
24.94%
31.48%
-6.54%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2024 is -11.84% vs 41.10% in Mar 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2024 is -44.56% vs 39.76% in Mar 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Meghmani Finechem Ltd stock-summary
stock-summary
Meghmani Finechem Ltd
Mid Cap
Chemicals
Epigral Limited was erstwhile incorporated as Meghmani Finechem Limited in 2007, which engaged in manufacturing and selling of Chlor Alkali & its Derivatives and also in Trading of Agrochemical products. The Company was incorporated as a subsidiary of Meghmani Organics Limited. Meghmani Finechem Limited (MFL) was demerged from Meghmani Organics Limited (MOL) as a going concern through the Scheme of Arrangement for Demerger and the said Scheme became effective from May 10, 2021.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."